20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
Rhea-AI Summary
20/20 BioLabs (Nasdaq:AIDX) will attend the Sidoti Micro-Cap Virtual Conference on May 20, 2026. CEO Jonathan Cohen will host a presentation from 3:15 PM to 3:45 PM ET in Track 1 and participate in one-on-one investor meetings.
Topics include recently reported quarterly results, recent partnership and licensing activity, and plans to scale the OneTest platform. Investors can access the webcast and schedule meetings through the conference website or conference representatives.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AIDX
On the day this news was published, AIDX declined 1.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peer stocks with momentum data were provided for the Healthcare/Medical Devices group, suggesting the -3.89% move in AIDX ahead of this conference-focused news looks stock-specific rather than part of a broader sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 12 | Licensing agreement | Positive | +6.3% | Exclusive PSA velocity algorithm license to enhance OneTest cancer platform. |
| Apr 07 | Distribution partnership | Positive | -5.5% | Evexia Diagnostics adds OneTest for Cancer to its practitioner platform. |
| Mar 31 | Earnings and updates | Positive | +0.0% | FY2025 revenue growth, margin expansion, lower opex, private placement completion. |
| Mar 27 | Funding award | Positive | +4.0% | Maryland funding over $520,000 for firefighter cancer screenings via OneTest. |
| Mar 24 | Tech license deal | Positive | -17.6% | Exclusive U.S. license to integrate CKD prediction into Longevity platform. |
Recent history shows several ostensibly positive partnership, licensing, and funding announcements followed by mixed to negative price reactions, indicating a tendency for the stock to sell off or remain flat on good news.
Over the past few months, AIDX reported FY2025 revenue growth and margin expansion, completed a $5.0M private placement, and advanced its AI-powered OneTest platforms. It announced Maryland firefighter funding of over $520,000, multiple licensing deals (including CKD and PSA velocity algorithms), and access partnerships like Evexia. Price reactions have been inconsistent, with gains after some licensing and funding news but notable declines after others, providing a mixed backdrop for this conference participation update.
Market Pulse Summary
This announcement highlights 20/20 BioLabs’ participation in the Sidoti Micro-Cap Virtual Conference on May 20, 2026, where management planned to review recent results, partnerships, and scaling plans for the OneTest platform. In recent months the company disclosed revenue growth, external funding, and several licensing and access deals. Investors may watch how effectively these initiatives translate into sustained adoption and whether ongoing registered resales disclosed in 424B3 filings affect trading dynamics.
AI-generated analysis. Not financial advice.
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference.
20/20 BioLabs’ Chief Executive Officer, Jonathan Cohen, will participate in one-on-one investor meetings and host a presentation from 3:15 PM ET to 3:45 PM ET in Track 1. Mr. Cohen will discuss the Company’s recently reported quarterly results, recent partnership and licensing activity, and the plans to scale the OneTest platform.
Sidoti Virtual Micro-Cap Virtual Conference
Date: Wednesday, May 20, 2026
Format: Presentation & Virtual 1x1 Meetings
Presentation: 3:15 – 3:45 PM ET in Track 1
Webcast: Click here
Attendee: Chief Executive Officer Jonathan Cohen
Conference Website: Click here
For more information on the Sidoti Micro-Cap Virtual Conference, or to schedule a one-on-one meeting with Jonathan Cohen, please contact your conference representative or you may also email your request to AIDX@mzgroup.us or call Chris Tyson at (949) 941-8235.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity, which measures inflammatory biomarkers, launched in February 2026. OneTest’s affordable, accurate, actionable tests can be conveniently accessed at home using new, upper arm collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD.
20/20 BioLabs’ pioneering Clinical Laboratory Innovation Accelerator, or CLIAx, is a shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the US without the expense of establishing and operating their own, independent lab. The Company’s legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. For more information visit 2020biolabs.com.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
